DURECT Corporation

Save the date for our fourth quarter and full year 2024 financial results & corporate update conference call on March 26th. For more information and to access the live webcast, visit: https://bit.ly/3DU4B3Q

Our CMO, Norman Sussman, MD, will participate in the upcoming Chief Medical Officer 360o Summit (#CMO360) April 7-8 in Boston to discuss “Enhanced strategic FDA collaboration” and network with CMOs across indications, modalities, and company stages. Learn more here: https://bit.ly/3DuUjHg

Our CMO, Norman Sussman, M.D, had a productive time at the recent American Association for the Study of Liver Diseases (AASLD)’s Emerging Topics Conference 2025, discussing the #AHFIRM trial data on alcohol-associated #hepatitis (#AH) with key hepatologists and alcohol-related liver disease experts.

Our CEO, Jim Brown, DVM, was featured in a recent Citeline Scrip Asks article to discuss therapeutic areas with the greatest advances for 2025. Read the article for his insights on #epigenetics' potential to revolutionize therapies across a wide range of diseases. More here: https://bit.ly/3XbMvRm

New research continues to show that rates of alcohol-associated #hepatitis (#AH) are increasing rapidly among adolescents and young adults, especially women, highlighting the need for effective interventions. Learn more in this HCPLive News article: https://bit.ly/4hrr0nA

Investigators of our completed AHFIRM Phase 2b study on alcohol-associated hepatitis (AH) will present trial data at American Association for the Study of Liver Diseases (AASLD)’s Emerging Topics Conference 2025. Learn more here: https://bit.ly/4gq0PNN

At DURECT, our mission is to revolutionize medicine through the power of #epigenetic modulation to address serious and life-threatening conditions. We are committed to improving patient outcomes through innovative treatments. Learn more about our mission: https://bit.ly/3WMk0db

On #WomenInScience Day, we are proud to spotlight WeiQi Lin, M.D., Ph.D, our Executive Vice President of Research and Development, Principal Scientist. Dr Lin has been instrumental in advancing DURECT’s #epigenetic regulator program from the lab into Phase 3 clinical development. We are honored to celebrate her achievements and leadership today and every day!

Our President and CEO, Jim Brown, will be presenting at Oppenheimer & Co. Inc.’s 35th Annual Healthcare Life Sciences conference. Tune in to the live webcast on February 11, 2025, from 2:00-2:30 p.m. ET for more. Read more information in our press release: https://bit.ly/3Q4HYwc

Volume 4 Issue 2 of ???????? ???????????????? is now available! Here is a preview of the latest content:?? ?? ???????????????? ????????????????? Hydroxyurea for Children and Adults with Hemoglobin SC Disease https://eviden.cc/3Zn494X? ?? Larsucosterol for the Treatment of Alcohol-Associated Hepatitis https://eviden.cc/3EehUvJ? ? A Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion https://eviden.cc/4apayla? ? Restrictive versus Liberal Transfusion in Myocardial Infarction — A Patient-Level Meta-Analysis https://eviden.cc/4gGsUjl? ? ???????????? ??????????????? Cardiopulmonary Exercise Testing https://eviden.cc/4aC6uOt? ?? ????????????????'?? ??????????? Should Low-Risk Pregnant Patients be Screened for Asymptomatic Bacteriuria? https://eviden.cc/4hoBwfa? ?? ?????????????? ?????????????? A 26-Year-Old Woman with Postpartum Abdominal Pain https://eviden.cc/4h3fdM5? ? ??????????, ????????!? How Linear Regression Works https://eviden.cc/4h8K227? ? Explore all the latest original research and specialty articles in the February issue: https://eviden.cc/current? #ClinicalTrials #MedicalResearch